Skip to Content

Sanctura Approval History

Sanctura (trospium chloride) is an antispasmodic, antimuscarinic agent indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.

Development History and FDA Approval Process for Sanctura

Aug  6, 2007Approval Indevus Announces FDA Approval of Sanctura XR
May 28, 2004Approval Sanctura Indevus Pharmaceuticals, Inc. - Treatment for Overactive Bladder

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.